<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82368">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996748</url>
  </required_header>
  <id_info>
    <org_study_id>DF277OTIII/11ES01</org_study_id>
    <nct_id>NCT01996748</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema</brief_title>
  <official_title>A Multicenter, Randomized, Parallel, Double-blind, Clinical Trial Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in Patients With Otic Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salvat</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salvat</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of DF277 for the treatment
      of otic eczema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Analysis of the itching change at the end of treatment.</measure>
    <time_frame>Baseline and days 4-8</time_frame>
    <safety_issue>No</safety_issue>
    <description>The analysis of the itching change at the end of treatment (mean itching on days 4-8 compared to baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in signs/ symptoms</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in itching at follow-up (mean itching on days 9-15 compared to baseline).
Change in mean scores of otoscopic signs (erythema, edema and scaling) at the end of treatment (day 8) compared to baseline (day 1).
Change in mean scores of otoscopic signs (erythema, edema and scaling) at follow- up (day 15) compared to baseline (day 1).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Otic Eczema</condition>
  <arm_group>
    <arm_group_label>DF277</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two administrations daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two administrations daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DF277</intervention_name>
    <description>Two administrations daily for 7 days</description>
    <arm_group_label>DF277</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two administrations daily for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 years or older

          -  Clinical diagnosis of otic eczema suitable for local treatment

        Exclusion Criteria:

          -  Other diseases.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratorios SALVAT, S.A.</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelone</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>October 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
